Chinese genome research and sequencing company BGI-Shenzhen has finalized its $117 million purchase of genome sequencing company Complete Genomics, marking the first acquisition of a U.S. public company by a Chinese acquirer. O'Melveny & Myers advised BGI; Latham & Watkins advised Complete Genomics.
March 21, 2013 at 02:23 AM
1 minute read
The original version of this story was published on Law.Com
Chinese genome research and sequencing company BGI-Shenzhen has finalized its $117 million purchase of genome sequencing company Complete Genomics Inc., marking the first acquisition of a U.S. public company by a Chinese acquirer.
The deal will likely lead to more Chinese investment in U.S. companies, attorneys for both sides say.
Deal Watch: Skadden, Sidley, Slaughter and S&C Lead Big Paper Deal, While Private Funds Grow Massive
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
